Merck's Sacituzumab Tirumotecan Meets Both Primary Endpoints in Phase 3 Trial for Endometrial Cancer
Merck (MRK) announced that its antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), met both primary endpoints—overall survival and progression-free survival—in a phase 3 trial for endometrial cancer. The TROP2-directed ADC showed statistically significant improvements at an interim analysis.
Tickers: $MRK
Topics: antibody-drug conjugates cancer treatment pharmaceuticals